24 January 2015 in CardioVascular and Interventional Radiology
16 June 2016 in Journal of Vascular and Interventional Radiology
7 November 2014 in CardioVascular and Interventional Radiology
7 October 2021 in Seminars in Interventional Radiology
Transarterial radioembolization using yttrium-90 (Y-90) microspheres is an important therapy in the management of unresectable primary liver tumors or hepatic metastases. While radioembolization is generally well-tolerated, it is not free from adverse events, and familiarity with the prevention and treatment of radioembolization-specific complications is an important component of patient care. This article aims to review radioembolization-specific toxicities stratified by hepatic, extrahepatic, and systemic effects, with a focus on preventing and mitigating radioembolization-induced morbidity.
1 March 2021 in Seminars in Interventional Radiology
Traumatic injury is the leading cause of death worldwide in younger patient populations and extremity trauma with associated vascular injury accounts for many trauma-related deaths. Iatrogenic injury is also a common cause of extremity vascular trauma and the incidence of iatrogenic injury will likely increase as endovascular techniques continue to become more ubiquitous. For many vascular injuries involving the extremities, surgical repair is viewed as the standard of care. Historically, endovascular techniques did not play a role in the treatment of these vascular injuries, rather they were utilized only as part of the diagnostic assessment; however, there is an increasing trend toward endovascular management of extremity vascular trauma. No validated, widely implemented algorithm to select patients for endovascular intervention exists. Transcatheter techniques, however, play an important role in the management of these patients. For arterial injuries, embolization can be used to rapidly achieve hemostasis if the vessel can be sacrificed. More advanced endovascular techniques such as stent-graft placement may be best employed in the context of isolated, proximal extremity injuries, although there is increasing literature supporting the use of advanced techniques for more distal arterial injuries. The management of peripheral venous trauma remains controversial; however, there is growing data describing successful endovascular management of some peripheral venous injuries. The purpose of this article is to review extremity vascular trauma, concepts of injury triage, endovascular techniques, and intraprocedural considerations.
11 December 2020 in Seminars in Interventional Radiology
Superselective transarterial radioembolization, or radiation segmentectomy, is a novel curative-intent therapy for patients with localized hepatocellular carcinoma (HCC). Radiation segmentectomy was developed as a means of addressing two concerns in the treatment of patients with HCC. First, by selectively treating the tumor-bearing hepatic Couinaud segments, the dose of radiation to normal parenchyma is limited and, consequently, the toxicity of radiation segmentectomy is minimized. Second, selective treatment allows for utilization of a higher dose of radiation, which correlates with a higher likelihood of objective response. Radiation segmentectomy hinges on a vital physical property of yttrium-90 (90Y): the average penetration of the β-radiation emitted by the decaying 90Y is 2.5 mm in tissue.[1] This allows the radiation to be confined to the perfused volume of tumor-bearing liver in which the 90Y microspheres are deposited by the catheter, while the rest of the liver remains radiation naive. Additionally, the microembolic nature of 90Y microspheres (compared with particles used in chemoembolization) allows for maintaining arterial patency, and avoids tissue ischemia and postembolization syndrome. Radiation segmentectomy may be performed in a subsegmental fashion or, as Riaz et al originally described, ablative radioembolization may be used to treat more than one segment.[2] G.E.J. is a consultant for Boston Scientific Corporation and Genentech. S.A.P. is a consultation for Boston Scientific Corporation and Bristol Meyer Squibb. Publication Date: 11 December 2020 (online) © 2020. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA